Related Experiment Video
Updated: Oct 28, 2026

Identification and Quantification of Deranged Metabolites in Critically Ill Patients Using NMR-Based Metabolomics
Published on: November 29, 2024
Metabolically Unhealthy Obesity: Novel Subtypes Defined by Integrated Metabolomics and Hematology
Xuan Huang1,2,3, Yuhong Liu1,2,3, Xiaoqian Zhu1,2,3
1Department of Cardiology, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Fuzhou 355000, China.
Abstract:
Objectives: The aim was to identify metabolic subtypes within metabolically unhealthy obesity (MUO) using integrated metabolomics and hematology data and evaluate their differential risks for cardiovascular-kidney-metabolic (CKM)-related outcomes. Methods: Among 62,341 obese UK Biobank participants (43,577 MUO; 18,764 non-MUO), least absolute shrinkage and selection operator regression selected 67 biomarkers from 96 metabolites and serological parameters, followed by K-means clustering. Cox proportional hazards models assessed subtype-specific associations with incident CKM-related outcomes over a median 14.81-year follow-up. Results: Four metabolic subtypes were identified within MUO, characterized by distinct amino acid, renal, and lipid profiles. Subtype-specific associations with CKM-related outcomes differed substantially. Compared with non-MUO participants, Subtype II and Subtype IV were associated with higher coronary heart disease risk (HR, 1.34; 95% CI, 1.11-1.61 and HR, 1.37; 95% CI, 1.15-1.64, respectively), Subtype IV was associated with lower atrial fibrillation risk (HR, 0.73; 95% CI, 0.60-0.90), Subtype III with higher heart failure risk (HR, 1.42; 95% CI, 1.10-1.82), and Subtype I with higher chronic kidney disease risk (HR, 1.52; 95% CI, 1.22-1.91). Conclusions: Integrated metabolomic and hematologic profiling identified variation in the metabolic profiles of individuals with MUO. The four subtypes showed different patterns of association with CKM-related outcomes, suggesting that MUO encompasses diverse metabolic profiles that may not be fully captured by conventional metabolic syndrome criteria.
Related Concept Videos
Obesity
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Type II Diabetes I: Introduction
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Regulation of Metabolism
Metabolic States of the Body: Fasting and Starvation